NCT04707352View on ClinicalTrials.gov

Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

PHASE3CompletedINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

March 26, 2023

Study Completion Date

March 26, 2023

Conditions

Heart Failure

Interventions

DRUG

Dapagliflozin

All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).

Trial Locations (1)

30003

Hospital Clinico Universitario Virgen de la Arrixaca, Murcia

All Listed Sponsors

collaborator

Spanish Society of Cardiology

OTHER

lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER

NCT04707352 - Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure . | Biotech Hunter | Biotech Hunter